Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis
European Journal of Surgical Oncology · 2026
DOI: 10.1016/j.ejso.2025.111165 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2026. Verfasst von P C M Andel und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital, Nieuwegein, the Netherlands. Elect…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Time-to-Treatment. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Guidelines recommend a time to adjuvant chemotherapy (TTC) within 12 weeks after pancreatic ductal adenocarcinoma (PDAC) resection. The aim of this study to evaluate the association between TTC and clinical outcomes in patients undergoing PDAC resection in the Netherlands. METHODS: Patients undergoing upfront, macroscopically radical PDAC resection (2014-2019) in the Netherlands were included. Patients were stratified into receiving no adjuvant chemotherapy, TTC 0-6 weeks, TTC 6-12 weeks, and TTC ≥12 weeks. Multivariable cox and logistic regression analyses were used to assess the association between TTC and overall survival (OS), and between TTC and adjuvant chemotherapy completion. RESULTS: Of 1459 patients, 543 (37 %) did not receive adjuvant chemotherapy, while TTC was 0-6 weeks in 245 (17 %), 6-12 weeks in 612 (42 %), and ≥12 weeks in 59 (4 %) patients. TTC in weeks (HR 0.99, 95 %CI 0.97-1.01, P = 0.39) and different TTC groups were not associated with OS (TTC 6-12 weeks vs TTC 0-6 weeks: HR 1.06, 95 %CI 0.76-1.49, P = 0.72, TTC ≥12 weeks vs TTC 0-6 weeks: (HR 0.62, 95 %CI 0.32-1.21, P = 0.16). Adjuvant chemotherapy completion was associated with improved OS (HR 0.81, 95 %CI 0.51-0.98, P = 0.04). Compared to TTC 0-6 weeks, TTC 6-12 weeks was associated with adjuvant chemotherapy completion (OR 1.57, 95 %CI 1.33-1.84, P < 0.001), while TTC ≥12 weeks was not (OR 1.13, 95 %CI 0.85-1.51, P = 0.39). CONCLUSION: TTC in patients with upfront PDAC resection was not associated with survival, but TTC 6-12 weeks was associated with adjuvant chemotherapy completion. These findings support prioritizing postoperative recovery rather than pushing early adjuvant chemotherapy initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital, Nieuwegein, the Netherlands. Electronic address: p.c.m.andel-2@umcutrecht.nl.
- Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital, Nieuwegein, the Netherlands; Department of Radiation Oncology, UMC Utrecht Cancer Center, Utrecht, the N…
- Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center & St. Antonius Hospital, Nieuwegein, the Netherlands.
- Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands; Cancer Center Amsterdam, the Netherlands.
- Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Surgery, Jeroen Bosch Hospital, Den Bosch, the Netherlands.
Zitieren
APA
Andel, P. C. M., van Goor, I. W. J. M., Biesma, N. C., Urban, L., Besselink, M. G., Bonsing, B. A., Bosscha, K., Busch, O. R., Cirkel, G. A., van Dam, R. M., van Eijck, C. H. J., Festen, S., Groot Koerkamp, B., van der Harst, E., de Hingh, I. H. J. T., Intven, M. P. W., Kazemier, G., van Laarhoven, H. W. M., Liem, M. S. L., …, & Dutch Pancreatic Cancer Group (2026). Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.111165
Vancouver
Andel PCM, van Goor IWJM, Biesma NC, Urban L, Besselink MG, Bonsing BA, et al. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. European Journal of Surgical Oncology. 2026. doi:10.1016/j.ejso.2025.111165
BibTeX
@article{Andel2026,
author = {Andel, P C M and van Goor, I W J M and Biesma, N C and Urban, L and Besselink, M G and Bonsing, B A and Bosscha, K and Busch, Olivier R and Cirkel, G A and van Dam, R M and van Eijck, C H J and Festen, S and Groot Koerkamp, B and van der Harst, E and de Hingh, I H J T and Intven, M P W and Kazemier, G and van Laarhoven, H W M and Liem, M S L and Los, M and de Meijer, V E and Nieuwenhuijs, V B and Roos, D and Schreinemakers, J M J and Stommel, M W J and van Tienhoven, G and Verdonk, R C and de Vos-Geelen, J and Wilmink, J W and de Wit, F and Wumkes, M L and Groot, V P and van Santvoort, H C and Daamen, L A and Molenaar, I Q and Dutch Pancreatic Cancer Group, Dutch Pancreatic Cancer Group},
title = {Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis},
journal = {European Journal of Surgical Oncology},
year = {2026},
doi = {10.1016/j.ejso.2025.111165}
}
EUVIMED